BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the result affects both treatment and cancer prevention in patients and relatives. Through the DNA-BONus study we offered BRCA1/2 testing and familial risk assessment to all new patients with breast (N=893) or ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Høberg-Vetti, Hildegunn, Bjorvatn, Cathrine, Fiane, Bent E, Aas, Turid, Woie, Kathrine, Espelid, Helge, Rusken, Tone, Eikesdal, Hans Petter, Listøl, Wenche, Haavind, Marianne T, Knappskog, Per M, Haukanes, Bjørn Ivar, Steen, Vidar M, Hoogerbrugge, Nicoline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867439/
https://www.ncbi.nlm.nih.gov/pubmed/26350514
http://dx.doi.org/10.1038/ejhg.2015.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867439/
https://www.ncbi.nlm.nih.gov/pubmed/26350514
http://dx.doi.org/10.1038/ejhg.2015.196

Ejemplares similares